Cavity Margin Status Is an Independent Risk Factor for Local-Regional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Before Breast-Conserving Surgery
Restricted accessResearch articleFirst published online December, 2011
Cavity Margin Status Is an Independent Risk Factor for Local-Regional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Before Breast-Conserving Surgery
The objection of this study is to investigate whether the cavity margin (CM) status has different predictive efficacy for local-regional recurrence (LRR) in patients who have received or have not received neoadjuvant chemotherapy (NAC) before breast-conserving surgery. We identified 61 patients who received NAC before breast-conserving surgery. A nonrandomized unmatched cohort of 295 patients without history of receiving NAC were also included in this study. Clinicopathological features and follow-up data were abstracted and analyzed. Patients in the NAC-treated group had more advanced diseases when compared with patients in the non NAC-treated group. With a median follow-up of 42 months, the LRR-free survival rate of patients with positive CMs was significantly lower than that of patients with negative CMs in the NAC-treated group. This distinction was not observed in the nonNAC-treated group. Univariate and multivariate analysis revealed that positive CM was the only independent predictive factor for LRR in the NAC-treated group but not in nonNAC-treated patients. CM status had different predictive efficacy for LRR in different settings. Association between CM status and LRR was observed in NAC-treated patients rather than nonNAC-treated patients. More extensive surgical treatment might be needed in NAC-treated patients when their CMs are positive.
Get full access to this article
View all access options for this article.
References
1.
MauriD., PavlidisN., IoannidisJ.P.Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.J Natl Cancer Inst2005; 97: 188–94.
GentiliniO., IntraM., GandiniS.Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.J Surg Oncol2006; 94: 375–9.
4.
ChenA.M., Meric-BernstamF., HuntK.K.Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.J Clin Oncol2004; 22: 2303–12.
5.
SanghaniM., BalkE., CadyB., WazerD.Predicting the risk of local recurrence in patients with breast cancer - An approach to a new computer-based predictive tool.American Journal of Clinical Oncology-Cancer Clinical Trials2007; 30: 473–80.
6.
SingletaryS.E.Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy.Am J Surg2002; 184: 383–93.
7.
FisherE.R., SassR., FisherB.Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity.Cancer1986; 57: 1717–24.
8.
HewesJ.C., ImkampeA., HajiA., BatesT.Importance of routine cavity sampling in breast conservation surgery.Br J Surg2009; 96: 47–53.
9.
PovoskiS.P., JimenezR.E., WangW.P., XuR.X.Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer.BMC Cancer2009; 9: 254.
10.
VeronesiU., BonadonnaG., ZurridaS.Conservation surgery after primary chemotherapy in large carcinomas of the breast.Ann Surg1995; 222: 612–8.
11.
NakamuraS., KenjoH., NishioT.Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy.Breast Cancer2002; 9: 15–9.
12.
Akashi-TanakaS., FukutomiT., SatoN.The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.Ann Surg2004; 239: 238–43.
13.
SchwartzG.F., HortobagyiG.N.Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania.Cancer2004; 100: 2512–32.
14.
GibsonG.R., LesnikoskiB.A., YooJ.A comparison of ink-directed and traditional whole-cavity re-excision for breast lumpectomy specimens with positive margins.Ann Surg Oncol2001; 8: 693–704.
15.
TaneiT., MorimotoK., ShimazuK.Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.Clin Cancer Res2009; 15: 4234–41.
16.
LanninD.R., GrubeB., BlackD.S., PonnT.Breast tattoos for planning surgery following neoadjuvant chemotherapy.Am J Surg2007; 194: 518–20.
17.
ChristyC.J., ThorsteinssonD., GrubeB.J.Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter.Ann Surg Oncol2009; 16: 697–702.
18.
ZavagnoG., GoldinE., MencarelliR.Role of resection margins in patients treated with breast conservation surgery.Cancer2008; 112: 1923–31.
19.
O'SullivanM.J., LiT., FreedmanG., MorrowM.The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery.Ann Surg Oncol2007; 14: 3133–40.
